title: Fine-tuning S1P therapeutics.
abstract: Sphingosine 1-phosphate receptor-1 (S1P(1)), a novel therapeutic target for multiple sclerosis, regulates lymphocyte trafficking, heart rate, and vascular function. The discovery of NIBR-0213, a competitive antagonist for S1P(1) that inhibits autoimmune inflammation while sparing bradycardia (Quancard et al., in this issue of Chemistry & Biology), suggests that fine-tuning of S1P(1) modulators may lead to novel immune modulators with better efficacy to adverse events ratio.
authors.forename: Hideru
authors.initials: H
authors.lastname: Obinata
authors.forename: Timothy
authors.initials: T
authors.lastname: Hla